drugset / Trial / NCT00959959
ARMOR1: Study of TOK-001 to Treat Castration Resistant Prostate Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether TOK-001 is safe and shows biological effect in the treatment of castration resistant prostate cancer (CRPC).
Timeline
- Start
- 2009-10
- Primary completion
- 2011-08
- Completion
- 2012-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | galeterone | Small molecule | 650 mg | — |
| Subject | galeterone | Small molecule | 975 mg | — |
| Subject | galeterone | Small molecule | 1300 mg | — |
| Subject | galeterone | Small molecule | 1950 mg | — |
| Subject | galeterone | Small molecule | 2600 mg | — |